A 70-year-old Caucasian man, N.B., presents to your emergency department with dyspnea, peripheral edema, and weight gain. He had a myocardial infarction five years ago and has progressive congestive heart failure (HF) (NYHA Class IV stage D). Currently, BP = 90/60, HR = 78, labs normal except BUN = 48, SrCr = 2 mg/dl, B-type natriuretic peptide = 1100 pg/ml. Physical assessment shows bilateral rales and warm and wet skin turgor. Current medications: furosemide 40 mg q.d., ramipril (Altace, Aventis) 2.5 mg q.d., carvedilol (Coreg, GlaxoSmithKline) 12.5 mg b.i.d., metolazone 2.5 mg p.r.n., weight gain (not taken last month). To treat his acutely decompensated HF and pulmonary edema, his physician prescribes furosemide 40 mg IV x 1. She asks whether to add nesiritide (Natrecor, Scios) or nitroglycerin (NTG) infusion.
Zaid Fadul, MD, FS, FAAFP, introduces the Nolla Derm app, what it might mean for pharmacists and their patients, and where AI prescribing is headed in the future.
From expert sources and recent data updates to a look at cases amid the ongoing respiratory virus season, this is an updated look at 2026 measles outbreaks in the US.
Zaid Fadul, MD, FS, FAAFP, joins for part 2 to discuss what greater adoption of AI across health care ecosystems might mean for pharmacists, patients, and more.
For pharmacies competing with CVS and relying on Caremark to serve patients, the prospect of those businesses operating under separate ownership is significant.